Editors note: This is part of a series about bankruptcy in the biopharma industry. Click here to see a running list of 2019 biopharma bankruptcies, and click here to see 31 biopharmas at high risk of bankruptcy for 2020.
Six years ago, Bind Therapeutics was flying high, with little idea how hard it would soon crash.
Headed into a public stock offering in 2013, the biotech, founded by top MIT and Harvard researchers, generated buzz with its lofty scientific ambitions. Company executives believed its nanomedicine platform, while only through Phase 1 tests, represented the next advance in cancer therapies.
Those dreams came undone within three years. As its experimental therapies struggled in clinical testing, Bind was punished by the market, and debt repayments forced the company into bankruptcy in 2016.
Bind may be a cautionary story in todays life sciences ecosystem, one that features biotechs going public at earlier stages and with heightened ambitions.
While bankruptcy is a rare outcome for biopharmas, 2019 has bucked that trend with an uptick in Chapter 11 filings. Eleven companies have declared bankruptcy so far this year, compared to an average of four per year during the past decade, according to a review of data tracked by the firm BankruptcyData.
That increase may forewarn of more companies falling to zero, industry experts said in interviews with BioPharma Dive, especially at a time of rising legal and political headwinds for the sector. After a decade of booming growth, the ballooning ranks of newly public biotechs may struggle to withstand market pressures.
I think theres a turning point now, said Andrew Hirsch, the former CEO of Bind, in an interview. I think its not sustainable.
Hirsch highlighted the rising prominence of early-stage platform companies, like Bind, going public in greater numbers and at larger valuations. That can bring steeper downside, he warned.
Things arent always going to work the first time, thats just the rule in this industry. A lot of times, companies are valued for perfection, said Hirsch, now Agios Pharmaceuticals chief financial officer.
If they are lucky and it works, thats great. But if you have a setback because youre doing novel things, the public markets can be a cruel place to be.
Biotech vastly outperformed the broader stock market over the past decade, and a steady inflow of capital supported more companies going public at rich valuations.
But those tides have turned. A leading biotech index has fallen more than 15% since peaking in the summer of last year, while the S&P 500 has ticked up nearly 13% in the same timeframe. The capital required for funding biopharmas ambitions is leaving too, with one Wall Street firm calculating $8.7 billion in net capital outflows this year rivaling a stretch in late 2015 and early 2016.
After years of outperformance, biotech has lagged the market for the past year
Price per share of a leading biotech index (XBI) and the S&P 500 (SPX) from January 2018 to October 2019 (indexed)
The base value of the index is trading value on Jan. 2, 2018.
Nami Sumida/BioPharma Dive
Investor anxiety is rising at a time when more companies are fighting for funding than in past decades. Evercore ISI analyst Josh Schimmer said this year hes noticed a marked shift in investor attitudes.
When they stumble, the markets are more unforgiving than ever, Schimmer said in an interview. They arent given second chances the way they used to be given. That may be a factor that does lead to a higher rate of bankruptcies.
And small biotechs arent the only ones facing elevated bankruptcy risk. The weight of thousands of lawsuits related to opioid marketing has already taken down Purdue Pharma and Insys Therapeutics. Several others, like Teva Pharmaceutical, Mallinckrodt and Amneal, are at risk of joining them.
The legal uncertainty has made these companies perceived as uninvestable, SVB Leerink analyst Ami Fadia said in an interview. Additionally, many of these pharmas are highly leveraged and face issues in generating cash going forward, she added.
Its pretty obvious that some of these companies are at high risk of bankruptcy, said Fadia, who covers several of these drugmakers including Mallinckrodt and Amneal.
To be sure, the effect of opioid liabilities is constrained to a comparatively small set of companies. But heading into an election year with drug pricing as a top issue, worries about capital fleeing the industry and a legal crackdown on opioid makers could be exacerbated by political threats as well.
Industry lobbyists have blasted HR3, the leading Democratic drug pricing proposal, saying it would trigger a nuclear winter by eroding the upside of biopharmas high-risk, high-reward investment premise.
If HR3 becomes law, it is lights out for a lot of very small biotech companies that are pre-revenue and depend on attracting capital, PhRMA CEO Stephen Ubl said at a recent media briefing.
Industry-specific concerns, of course, come against the backdrop of fears of a broader economic slowdown. Financial analysts have flagged recession signals in the U.S., which, if materialized, would further squeeze the industry.
It may be coming, in which capital itself is scarcer for companies, said Bob Eisenbach, a lawyer at Cooley specializing in bankruptcies. And when that happens, it puts pressure even on good companies.
Biopharmas are structured to avoid bankruptcies. Pre-revenue companies typically carry little debt and have little to restructure through a bankruptcy court if their pipeline fizzles.
Privately held biotechs that suffer clinical failures can also avoid bankruptcy by having their financial backers buy them out, saving face for those venture capitalists.
It just disappears into this great maw of the biotech universe, said Kevin Kinsella, a venture capitalist and founder of Avalon Ventures, referring to distressed biotechs in an interview.
Having launched more than 100 biopharmas, including prominent names like Vertex, Neurocrine and Onyx, Kinsella said hes been lucky enough to avoid getting entangled in any bankruptcies.
Someone absolutely failing, shutting the doors and turning off the lights, you dont really see that a lot in our industry, he said.
Drug companies, both young and old, derive value from ideas and hope more than tangible assets or resources. Just last year, early-stage platform companies like Moderna Therapeutics and Rubius Therapeutics went public with multi-billion dollar valuations despite lacking profits and significant clinical data.
But investor attitudes appear to have shifted. Rubius stock, for instance, has dropped more than 70% since its IPO. While up this month, shares in Moderna are 30% off their 52-week high in May.
Speaking generally about platform companies, Binds former CEO said market sentiment has turned.
Investors have lost their appetite for companies going public with preclinical data, Hirsch said.
Youre probably going to see more of these situations going forward, where a company is preclinical, went public and is left on their own and has to raise additional money from the public markets and they flounder.
Yet even floundering biotechs can persist for years, even decades. Long-standing industry veterans like Xoma, Novavax and Geron have survived in as-yet fruitless searches for their first drugs, suffering clinical failures along the way. Despite accumulated deficits exceeding $1 billion, these companies can find the necessary capital to keep chugging along.
Theres always someone else whos willing to bet the next discovery is around the corner, or the next asset, or if we get this clinical trial enrolled and finished, all will be good, Kinsella said. Theres always hope.
Besides selling hope, biopharmas, like all businesses, have practical options to stave off bankruptcy. Restructuring and raising cash are the main focuses, turnaround experts said.
Corporate restructurings typically shrink the business, either by laying off employees, selling assets or killing off R&D projects. Raising capital can include licensing rights to experimental therapies, taking on debt or tapping the public markets for secondary stock offerings.
If those options are exhausted, M&A can be another way out for shareholders. Firms like Deerfield Management, Hercules Capital and Highbridge Capital Management often aid distressed biotechs in such endeavours.
Deerfield, for instance, reached deals to finance R&D costs for Dynavax and helped fund Melinta Therapeutics acquisition of an infectious disease business.
A last resort can be merging with another struggling biotech, or becoming the shell in a reverse merger for another company seeking an easy path to a public listing.
Both happened in just the past few weeks. Foamix Pharmaceuticals and Menlo Therapeutics merged into one dermatology company, while NewLink Genetics was the shell through which Lumos Pharma joined public markets.
These strategies act as moats that insulate a high-risk industry from bankruptcy. In recent years, they have worked tremendously well. Among the 333 biopharmas that have gone public since 2012, just 3% filed for bankruptcy while 6% became reverse merger shells and 10% exited via M&A, according to data tracked by Evercore ISI.
But with 2019 looking shaky for biopharma, some have begun to wonder how markets will respond.
The last few years have featured record levels of capital raising, according to the investment bank Jefferies, which tallied 100 initial public offerings and 270 follow-on raises in 2018 and 2019 that drummed up tens of billions in cash.
At the same time, the number of public small and mid-sized biotechs has doubled in the past decade. There arent just more of these smaller firms; they also are worth more and consume more capital on average. From 2010 to present, these companies have seen their typical market values double, R&D budgets triple and cash burn rates quadruple, Jefferies found.
The annual burn rate for these biotechs, which includes market values from $200 million to $5 billion, has increased from $20 million to $80 million. Jefferies analyst Michael Yee credited that to free-flowing capital, more platform companies and an arms race in oncology.
Biotechs impressive market performance has made that possible. A leading biotech index, for instance, outperformed the S&P 500 by 30% since the market bottomed out in March 2009.
But of late, biotech has struggled, creating a tougher environment to raise cash.
The question is whether this is sustainable if market and macro conditions get tougher and political uncertainty gets more obvious, forcing companies to tighten their belts to ride out 2020, Yee wrote.
2019 has brought an uptick in industry bankruptcy filings
Credit: Data from Bankruptcy Data
Conditions have clearly worsened by some metrics, such as the amount of money invested in healthcare- or biotech-dedicated funds. Data tracked by a Piper Jaffray found $8.7 billion in investment has left such funds in 2019. Ten of the past 12 weeks have registered net capital outflows, a streak a Piper Jaffray analyst called seemingly the new normal.
Billions of dollars flowed out of biotech in 2015 and 2016, too, at a time when many biotech shares were falling and the prospect of a Hillary Clinton presidency had raised investor fears on drug pricing.
Biotech weathered that storm, with few companies entering bankruptcy, and has grown since. Going forward, a critical question will be gauging whether the sector is on a new trajectory or if it will emerge from this period relatively unscathed.
Getting investor attention is harder than ever to begin with, said Evercores Schimmer. For a company that has faltered, even if they are doing the right thing, its a struggle.
- What is Nanomedicine? : Center for Nanomedicine - March 31st, 2020
- Nanomedicine | medicine | Britannica - March 31st, 2020
- Nano Medicine: Meaning, Advantages and Disadvantages - March 31st, 2020
- Nanomedicine: Nanotechnology, Biology and Medicine ... - March 31st, 2020
- What Might be the Best Way to Delivery Nanoparticle Therapy for Cancer? - Genetic Engineering & Biotechnology News - March 31st, 2020
- Nano Healthcare Technology For Medical Equipment Market Business Opportunities, 2020 Trends, Challenges and Standardization, Research, Key Players and... - March 31st, 2020
- Global Healthcare Nanotechnology Market 2019 Present Status and Future Opportunities by Major Companies Typs and Applications 2024 - The Fuel Fox - March 31st, 2020
- Nanobiotix 2019 Q4 and Annual Revenues - BioSpace - February 29th, 2020
- Dying Of Flu, College Student Used Cellphone To Call 911. He Died When Police Couldn't Find His Location. - Kaiser Health News - February 29th, 2020
- Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead... - January 25th, 2020
- Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form N | IJN - Dove Medical Press - January 25th, 2020
- Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN - Dove Medical Press - January 25th, 2020
- Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating | IJN - Dove Medical Press - January 25th, 2020
- Healthcare Nanotechnology (Nanomedicine) Market Share, Size, Future Demand, Global Research, Top Leading Player, Emerging Trends and Forecast to 2015 ... - January 25th, 2020
- Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - Business Wire India - January 25th, 2020
- I asked Tanzanians about studying in China: here's what they said - The Conversation Africa - January 25th, 2020
- The Future Of Nano Medicine - January 19th, 2020
- New Approaches in Breast Cancer Therapy Through Green Nanotechnology a | IJN - Dove Medical Press - January 19th, 2020
- Controlled phage therapy hints at future alternative to antibiotics - New Atlas - January 19th, 2020
- A New Old Therapy - The UCSB Current - January 19th, 2020
- Most engineered nanoparticles enter tumours through cells not between them, U of T researchers find - News@UofT - January 19th, 2020
- Canterbury father and son's invention will revolutionise medical treatment - Stuff.co.nz - December 28th, 2019
- Rewind 2019: A Look Back at Significant Developments in Indian Science This Year - The Weather Channel - December 27th, 2019
- Electroplating method makes conductive nanostraws for injecting into and sampling from cells - Chemical & Engineering News - December 3rd, 2019
- Protein-Protected Metal Nanoclusters That Behave Like Natural Enzymes - Advanced Science News - December 3rd, 2019
- Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Co | IJN - Dove Medical Press - December 3rd, 2019
- Biochips Technologies, Companies, Applications & Markets, 2028 - 94 Companies are Included Along with a Listing of 121 Collaborations Between... - December 3rd, 2019
- Invicro LLC Joins Accenture's INTIENT Network to Help Advance Innovation in Drug Discovery and Scientific Research - BioSpace - December 3rd, 2019
- Nanoparticle therapy shows promise for treatment of rare cancer - The Brown Daily Herald - November 22nd, 2019
- At 9.6% CAGR, Healthcare Nanotechnology Market Global Industry to Reach Valuation over 306100 Million USD by 2025 - Markets Gazette 24 - November 22nd, 2019
- Nanotherapies for Rheumatoid Arthritis: Advantages, Challenges, and Future Direction - Rheumatology Advisor - November 22nd, 2019
- World Pancreatic Cancer Day: increasing awareness and inspiring action - UNSW Newsroom - November 22nd, 2019
- Healthcare Nanotechnology Market Needs and Demand Analysis 2019 to 2025 - The Chicago Sentinel - November 13th, 2019
- Medical equipment to be infection-free now, says study - Zee News - November 12th, 2019
- Advances in nanomedicine for the treatment of ankylosing spondylitis | IJN - Dove Medical Press - November 1st, 2019
- Market Share in Nanotechnology and Nanomedicine for Treatment of Viral Infections Could Reach Tens of Billion Dollars - P&T Community - November 1st, 2019
- A highly biocompatible and intravenous injectable hafnium oxide nanocrystal synthesized to enhance radiaotherapy efficacy for cancer treatment -... - November 1st, 2019
- Doheny and UCLA Stein Eye Institutes Welcome Kaustabh Ghosh, PhD, to the Scientific and Clinical Research Faculty - PRNewswire - November 1st, 2019
- SUNY Potsdam chemistry professor awarded grant from National Institutes of Health - NNY360 - October 1st, 2019
- Improving 131I Radioiodine Therapy By Hybrid Polymer-Grafted Gold Nano | IJN - Dove Medical Press - October 1st, 2019
- MagForce AG to host Lunch Symposium on Local Therapies in Malignant Gliomas during the 19th European Congress of Neurosurgery (EANS2019) - BioSpace - October 1st, 2019
- Synthetic networks with tunable responsiveness, biodegradation, and molecular recognition for precision medicine applications - Science Advances - October 1st, 2019
- Self-Assembly Of Retinoid Nanoparticles For Melanoma Therapy | IJN - Dove Medical Press - October 1st, 2019
- Nanomanipulator Market Upcoming Trends, Revenue, Key Manufactures and Competitive Analysis till 2025 - One Digi Click - October 1st, 2019
- First-of-its-kind trial in ALS spurs hope for brutal disease - BioPharma Dive - October 1st, 2019
- FBI Investigation Targets Trump Booster Peter Thiel’s VC Firm - September 14th, 2019
- YouTube Influencers Are Mentally Collapsing From Stress - September 14th, 2019
- Watch SpaceX Test Its Crew Dragon’s Escape System - September 14th, 2019
- MIT Team “Accidentally” Invents Blackest Material in Existence - September 14th, 2019
- A Driver Tricked Uber’s Algorithm, Sexually Assaulted a Passenger - September 14th, 2019
- Toyota Wants to Slather Solar Panels All Over Its Prius Hybrid - September 14th, 2019
- A Runaway Star Is Escaping a Black Hole at 1.2 Million MPH - September 14th, 2019
- Putin Critic Uses Drone to Save Hard Drives Before Police Raid - September 14th, 2019
- Airbus Planes Will Track How Often Passengers Go to the Bathroom - September 14th, 2019
- Watch a Robot Fish Fly by Shooting Water out of Its Rear - September 14th, 2019
- Residents Are Trying to Flee Russian Town Where Snow Turned Black - September 14th, 2019
- This Startup Will Send DNA From Your Spit to the Moon for $99 - September 14th, 2019
- Horrifying Study: Corpses Thrash Around For a Year After Death - September 14th, 2019
- French Gov Official Warns Facebook: Libra Is Not Welcome Here - September 14th, 2019
- Watch a Tesla Model X Blast Through Deep Flood Waters - September 14th, 2019
- Milky Way’s Giant Black Hole Lets out Two Giant, Radioactive Burps - September 14th, 2019
- Instagram Keeps Accidentally Flagging Fish Photos as Offensive - September 14th, 2019
- MIT Community Horrified by Famed Researcher’s Epstein Outburst - September 14th, 2019
- Unlike MIT, Harvard Cut Off Epstein Donations After Conviction - September 14th, 2019
- Can You Tell Which of These Models Is CGI? - May 28th, 2019
- We Asked an AI to Finish Real Elon Musk Tweets - May 28th, 2019
- Watch a Super-Strong Robot Dog Pull a Three-Ton Airplane - May 28th, 2019
- Asteroid Flying by Earth Is so Big It Has Its Own Moon - May 28th, 2019
- United Nations: Siri and Alexa Are Encouraging Misogyny - May 28th, 2019
- New Law Could End Robocalling Once and For All - May 28th, 2019
- Scientists Set New Temperature Record for Superconductivity - May 28th, 2019
- Elevate Your Leadership and Grow Your Business at Your Clouds Can 2019 - May 28th, 2019
- NASA’s Moon Mission Leader Just Quit After Only Six Weeks - May 28th, 2019
- Watch a Tesla in an Underground Tunnel Race One on the Street - May 28th, 2019
- SpaceX Just Unleashed 60 Starlink Satellites Into Orbit - May 28th, 2019
- Elon Musk Ridicules Jeff Bezos’ Plan For Space Colonies - May 28th, 2019
- See China’s Newly Unveiled Maglev Train - May 28th, 2019
- Here’s How NASA Prepares Its Spacecraft for Mars - May 28th, 2019
- This Robot Scans Preschoolers’ Faces Daily for Signs of Sickness - May 28th, 2019
- New Research: The Oceans Are Slowly Leaking Into the Earth - May 28th, 2019